NCT02184013Active, not recruiting
Correlation of the Arrhythmia Mechanism and Substrate to Ablate Persistent Atrial Fibrillation Study
Correlation of Arrhythmia Mechanism and Substrate to Ablate Persistent Atrial Fibrillation:A Pilot Study
Source: ClinicalTrials.gov · Last updated 30 Sept 2026
Brief summary (registry, in English)
This is a pilot study to assess the usefulness of ECG mapping, and enhanced MRI and PET scan imaging in identifying atrial fibrosis and arrhythmia circuits involved in persistent atrial fibrillation and in guiding an innovative AF catheter ablation strategy. It is hypothesized that identifying these critical arrhythmia circuits and atrial fibrosis with enhanced imaging and performing an individualized innovative AF catheter ablation will result in higher procedural success rates.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 52 (actual)
- First submitted
- 2 Jul 2014
- Start date
- Sept 2015
- Primary completion date
- Aug 2018
- Lead sponsor
- Ottawa Heart Institute Research Corporation
- Diseases
- Atrial fibrillation
- NCT number
- NCT02184013
What you commit to
- Study type: Interventional
- Participants enrolled: 52
- From Sept 2015 to the primary completion date, Aug 2018
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of previous catheter or surgical ablation for AF
- contraindication to systemic oral anticoagulation therapy
- Contraindication to MRI Imaging (e.g. permanent pacemaker, metallic implants, etc)
Other illness
- Severe valvular disease (mitral/aortic stenosis or regurgitation);
Lab values
- Chronic kidney disease and creatinine clearance \<50ml/min.
Other
- Presence of intracardiac thrombus
- Subjects with reversible causes of AF
- Antero-posterior left atrial dimension \> 60 mm on echocardiography
- Subjects that are pregnant or breastfeeding;
Who the study is looking for
- Age ≥18 years and ≤ 80 years;
- Symptomatic persistent AF AND clinically indicated for AF catheter ablation
- At least one episode of AF lasting more than 7 days, documented on 12-lead ECG, Holter monitor, 2-week loop monitor or trans-telephonic monitor (TTM) within 12 months of enrollment in the study
- Able to provide informed consent.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Ottawa Heart Institute Coordinator of this site? Confirm its status | Ottawa | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.